Bile Acids and Portal Hypertension

The recent discovery of bile acid (BA) receptors and a better delineation of the multiple roles of BAs in relevant biological processes have revamped BA research. The vasoactive actions of BAs were recognized more than three decades ago but the underlying mechanisms of the BA-induced vasorelaxation...

Full description

Bibliographic Details
Main Authors: Juan Pablo Arab, Francisco Barrera, Marco Arrese
Format: Article
Language:English
Published: Elsevier 2017-11-01
Series:Annals of Hepatology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119310464
id doaj-329a17f8e4dd4c31ab197d0d72583b24
record_format Article
spelling doaj-329a17f8e4dd4c31ab197d0d72583b242021-06-09T05:53:14ZengElsevierAnnals of Hepatology1665-26812017-11-0116S83S86Bile Acids and Portal HypertensionJuan Pablo Arab0Francisco Barrera1Marco Arrese2Departamento de Gastroenterología, Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago, Chile; Division of Gastroenterology and Hepatology, Mayo Clinic. Rochester, MN, USADepartamento de Gastroenterología, Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago, Chile; Correspondence and reprint request:The recent discovery of bile acid (BA) receptors and a better delineation of the multiple roles of BAs in relevant biological processes have revamped BA research. The vasoactive actions of BAs were recognized more than three decades ago but the underlying mechanisms of the BA-induced vasorelaxation are now being clarified. Recent evidence shows that the BA receptors FXR and TGR5 are expressed in endothelial cells and may have important effects on both systemic and portal circulation. The availability of genetically engineered mice with ablation of BA receptors and the development of BA receptor agonists has allowed to explore the modulation of FXR and, in a lesser extent, of TGR5 in the setting of portal hypertension (PHT) with promising results. In this review, we summarize recent data on how BA-dependent pathways influence several processes that impact in PHT and the preclinical data showing that pharmacological modulation of those pathways may hold promise in the treatment of PHT.http://www.sciencedirect.com/science/article/pii/S1665268119310464Bile acidsHepatic flowPortal hypertensionCirrhosisFarnesoid X receptorFibrosis
collection DOAJ
language English
format Article
sources DOAJ
author Juan Pablo Arab
Francisco Barrera
Marco Arrese
spellingShingle Juan Pablo Arab
Francisco Barrera
Marco Arrese
Bile Acids and Portal Hypertension
Annals of Hepatology
Bile acids
Hepatic flow
Portal hypertension
Cirrhosis
Farnesoid X receptor
Fibrosis
author_facet Juan Pablo Arab
Francisco Barrera
Marco Arrese
author_sort Juan Pablo Arab
title Bile Acids and Portal Hypertension
title_short Bile Acids and Portal Hypertension
title_full Bile Acids and Portal Hypertension
title_fullStr Bile Acids and Portal Hypertension
title_full_unstemmed Bile Acids and Portal Hypertension
title_sort bile acids and portal hypertension
publisher Elsevier
series Annals of Hepatology
issn 1665-2681
publishDate 2017-11-01
description The recent discovery of bile acid (BA) receptors and a better delineation of the multiple roles of BAs in relevant biological processes have revamped BA research. The vasoactive actions of BAs were recognized more than three decades ago but the underlying mechanisms of the BA-induced vasorelaxation are now being clarified. Recent evidence shows that the BA receptors FXR and TGR5 are expressed in endothelial cells and may have important effects on both systemic and portal circulation. The availability of genetically engineered mice with ablation of BA receptors and the development of BA receptor agonists has allowed to explore the modulation of FXR and, in a lesser extent, of TGR5 in the setting of portal hypertension (PHT) with promising results. In this review, we summarize recent data on how BA-dependent pathways influence several processes that impact in PHT and the preclinical data showing that pharmacological modulation of those pathways may hold promise in the treatment of PHT.
topic Bile acids
Hepatic flow
Portal hypertension
Cirrhosis
Farnesoid X receptor
Fibrosis
url http://www.sciencedirect.com/science/article/pii/S1665268119310464
work_keys_str_mv AT juanpabloarab bileacidsandportalhypertension
AT franciscobarrera bileacidsandportalhypertension
AT marcoarrese bileacidsandportalhypertension
_version_ 1721388804925816832